Paper Details

  1. Home
  2. Paper Details

Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.

Author: FonsecaRafael, RajkumarS Vincent

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the effectiveness of two new treatment strategies for multiple myeloma, a type of blood cancer: 1) using bortezomib and dexamethasone (VD) as the initial treatment, and 2) adding bortezomib to lenalidomide and dexamethasone (VRD) as the initial treatment. The study aims to determine which approach leads to better long-term control of the disease and if these new regimens can extend survival for patients with myeloma.
Paper Details　
Original Abstract of the Article :
In recent years, we have seen tremendous progress in our ability to achieve durable responses in patients with multiple myeloma. At the center of this progress, we have the development of 2 unrelated classes of drugs: proteasome inhibitors such as bortezomib and immunomodulatory drugs such as thalid...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3816/CLM.2008.n.046

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: A Camel's Battle Against a Shifting Sandstorm

This research explores the use of bortezomib and lenalidomide in the treatment of multiple myeloma, a type of blood cancer. Imagine a camel, facing a relentless sandstorm, its body battling a persistent and destructive force. This study investigates the potential of these drugs to achieve durable responses and prolong survival for patients with this challenging disease.

Combating the Storm: A Camel's Quest for Remission

The study compares two treatment strategies: bortezomib/dexamethasone (VD) and bortezomib/lenalidomide/dexamethasone (VRD), both utilizing a proteasome inhibitor (bortezomib) and an immunomodulatory drug (lenalidomide or thalidomide). It's like a camel, equipped with a diverse arsenal of weapons, strategically fighting against the ever-shifting sandstorm. The study aims to determine which strategy leads to more effective long-term disease control and potentially prolongs the life of patients.

A Camel's Resilience: Seeking Durable Responses

This research highlights the importance of finding effective treatment strategies for multiple myeloma, a complex and often challenging disease. It emphasizes the need for ongoing research to develop new and improved therapies that can achieve durable responses and improve the quality of life for patients. It's like a camel, enduring a long and arduous journey, seeking the strength and resilience to overcome the challenges it faces.

Dr.Camel's Conclusion

This study explores the potential of bortezomib and lenalidomide in the treatment of multiple myeloma, highlighting the ongoing quest to find more effective and durable treatment strategies for this challenging disease.

Date :
  1. Date Completed 2008-12-31
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

18854289

DOI: Digital Object Identifier

10.3816/CLM.2008.n.046

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.